IP Verse

Novel Treatment Of Mitochondrial Diseases - EP3606522

The patent EP3606522 was granted to Khondrion on Jul 12, 2023. The application was originally filed on Sep 5, 2017 under application number EP17758900A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3606522

KHONDRION
Application Number
EP17758900A
Filing Date
Sep 5, 2017
Status
Granted And Under Opposition
Jun 9, 2023
Grant Date
Jul 12, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SULFATEQApr 10, 2024HOYNG ROKH MONEGIERADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2005067303
DESCRIPTIONWO2012019029
DESCRIPTIONWO2012019032
DESCRIPTIONWO2014011047
INTERNATIONAL-SEARCH-REPORTUS2009118257
INTERNATIONAL-SEARCH-REPORTWO2014011047
INTERNATIONAL-SEARCH-REPORTWO2017060432
OPPOSITIONWO2014011047
OPPOSITIONWO2014098586

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "History of Changes for Study: NCT02544217 A Dose-escalating Clinical Trial With KH176", ClinicalTrials.gov NCT02544217, (20160502), ClinicalTrials.gov NCT02544217, URL: https://clinicaltrials.gov/study/NCT02544217?tA=1&B=2&C=Side-by-Side#StudyPageTop, XP093184166-
OPPOSITION- Anonymous, "KHENERGY: completion of recruitment and first-in-patient dosing", Khondrion BV, (20161024), pages 1 - 7, Khondrion BV, URL: https://www.khondrion.com/khenergy-completion-of-recruitment-and-first, XP093184143-
OPPOSITION- Anonymous K, "The KHENERGY Study (KHENERGY)", ClinicalTrials.gov Identifier: NCT02909400, (20180223), ClinicalTrials.gov Identifier: NCT02909400, URL: https://clinicaltrials.gov/study/NCT02909400, XP093184177-
OPPOSITION- Ema, "Guideline on the investigation of drug interactions,", EMA CPMP/EWP/560/95/Rev. 1 Corr. 2**, (20120621), pages 1 - 59, EMA CPMP/EWP/560/95/Rev. 1 Corr. 2**, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf, XP093184173-
OPPOSITION- Emea, "ICH: E 14: The Clinical Evaluation of QT/QTs Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic drugs - Step 5", EMEA CHMP/ICH/2/04, (20051101), EMEA CHMP/ICH/2/04, URL: https://www.ema.europa.eu/en/ich-e14-clinical-evaluation-qt-qtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-scientific-guideline, XP093184148-
OPPOSITION- Emea, "ICH Topic S 7 B The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Step 5", EMEA CPMP/ICH/423/02, (20051101), EMEA CPMP/ICH/423/02, XP093184154-
OPPOSITION- Fda, "Drug Interaction Studies - Study design, Data Analysis, and Implications for Dosing and Labelling", Guidance for Industry, (20060908), Guidance for Industry, XP093184170-
OPPOSITION- Ich Expert Working Group, "SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A ", ICH HARMONISED TRIPARTITE GUIDELINE, (20001108), ICH HARMONISED TRIPARTITE GUIDELINE, URL: https://database.ich.org/sites/default/files/S7A_Guideline.pdf, XP093184150-
OPPOSITION- Koopman W. J., Beyrath J; C-W Fung; Koene S; Rodenburg R J; Willems P H; Smeitink J A, "Supplemental Figures. Mitochondrial disorders in children: toward development of small-molecule treatment strategies", EMBO Molecular Medicine, (20160401), vol. 8, no. 4, XP093184182-
OPPOSITION- Hajmousa Ghazaleh; Vogelaar Pieter; Brouwer Linda A.; van der Graaf Adrianus C.; Henning Robert H.; Krenning Guido, "The 6-chromanol derivate SUL-109 enables prolonged hypothermic storage of adipose tissue-derived stem cells", Biomaterials, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20161209), vol. 119, doi:10.1016/j.biomaterials.2016.12.008, ISSN 0142-9612, pages 43 - 52, XP029872228
OPPOSITION- Garrido Amanda; Lepailleur Alban; Mignani Serge M.; Dallemagne Patrick; Rochais Christophe, "hERG toxicity assessment: Useful guidelines for drug design", European Journal of Medicinal Chemistry, Elsevier Masson, (20200403), vol. 195, doi:10.1016/j.ejmech.2020.112290, ISSN 0223-5234, page 112290, XP086143990
OPPOSITION- Vogelaar PC; Nakladal D; Swart DH; Tkáčiková Ľ; Tkáčiková S; van der Graaf AC; Henning RH; Krenning G, "Towards prevention of ischemia-reperfusion kidney injury: Pre-clinical evaluation of 6-chromanol derivatives and the lead compound SUL-138✰", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20211003), vol. 168, doi:10.1016/j.ejps.2021.106033, ISSN 0928-0987, XP086895294
OPPOSITION- Malik Marek, Hnatkova Katerina, Ford John, Madge David, "Near-Thorough QT Study as Part of a First-In-Man Study", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20081001), vol. 48, no. 10, doi:10.1177/0091270008323261, ISSN 0091-2700, pages 1146 - 1157, XP055950742
OPPOSITION- Rohatagi Shashank, Carrothers Timothy J., Kuwabara-Wagg Jon, Khariton Tatiana, "Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20091101), vol. 49, no. 11, doi:10.1177/0091270009341184, ISSN 0091-2700, pages 1284 - 1296, XP055950751
OPPOSITION- W. J. Koopman, J. Beyrath, C.-W. Fung, S. Koene, R. J. Rodenburg, P. H. Willems, J. A. Smeitink, "Mitochondrial disorders in children: toward development of small-molecule treatment strategies", EMBO Molecular Medicine, Wiley-Blackwell, US, US , (20160401), vol. 8, no. 4, doi:10.15252/emmm.201506131, ISSN 1757-4676, pages 311 - 327, XP055420844

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents